[Hormone receptor status in adenomatous hyperplasia of the endometrium and endometrial carcinoma].
1. In glandular hyperplasia and endometrial carcinoma a correlation exists between the increased proliferation rate and the rise of the ER/PR-quotient. 2. The decline of both receptor concentrations and the increase of ER/PR-Quotient in the tumor and neighbouring, non-diseased tissue was demonstrated with increasing dedifferentiation, comparing endometrial carcinoma of different stages (G1 and G2, respectively). 3. In adenomatous hyperplasia the two receptors are significantly increased compared to normal cycling and glandular-hyperplastic endometrium, respectively; there the ER/PR-quotient is smaller than 1. After gestagen therapy decrease of both receptor concentrations demonstrates the success of therapy on one hand. On the other hand the higher decrease of PR shows, that duration and success of therapy could be limited temporally. 4. In endometrial carcinoma, especially in case of progression, recurrence and/or metastases, the determination of receptor status could be useful for therapy conception in the individual patient.
Martin
R
R
Institut für Klinische Chemie und Laboratoriumsdiagnostik, Karl-Marx-Universität Leipzig.
Lehmann
E
E
Leitsmann
H
H
D000328:Adult; D002277:Carcinoma / Q000737:chemistry*; D004714:Endometrial Hyperplasia / Q000378:metabolism*; D005260:Female; D006801:Humans; D008598:Menstruation / Q000502:physiology; D008875:Middle Aged; D010347:Patient Care Planning; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D014594:Uterine Neoplasms / Q000737:chemistry*
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
Hormonrezeptorstatus bei adenomatöer Hyperplasie des Endometriums und Endometriumkarzinom.